Try our mobile app
ROSELAND, N.J., March 31, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update and announced financial results for the year ending December 31, 2022.
Arjan Haverhals, CEO and President of Milestone Scientific, stated, “2022 was a productive year for the Company as we advanced the rollout of the CompuFlo® Epidural System across key hospitals, healthcare systems and pain management clinics. Following up on the issuance of a Category III Current Procedural Terminology (CPT®) code to identify the use of our patented technology will be a focus area in 2023. We believe this would potentially allow billing and payment pathways for healthcare personnel who choose to use our technology for coverage and discretionary payment by payers such as Medicare and Medicaid as well as commercial health plans. More recently, we received 510(k) FDA clearance for use of the CompuFlo Epidural System in the thoracic region of the spine, including the cervical thoracic junction, where the incidence rates of morbidity are believed to be much higher than in the lumbar spine region. This has helped drive the adoption of our CompuFlo Epidural System within a number of prominent pain management clinics. We were also granted registration with the U.S. Government’s System for Award Management (SAM) and are actively pursuing U.S. Federal Supply Service (FSS) approval for the CompuFlo® Epidural Instrument.”
“Within our Dental Segment, we made a number of key changes to our overall sales and marketing strategy that we believe will support and enhance our long-term growth. In the U.S., we launched a new online store for US dentists to order the STA Single Tooth Anesthesia® System Instruments and Handpieces, and ended the agreement with our prior distributor as we exited 2022. This new site went live on January 3, 2023. While this change in US distribution strategy resulted in lower fourth quarter of 2022 sales, as the prior distributor wound down its operations, we expect our new direct online channel will provide us with a closer relationship to our customers and better margins. Additionally, we experienced continued growth in international sales, excluding China. Overall, we remain encouraged by the growing interest in both our dental and medical products.”
For the years ended December 31, 2022, and 2021, revenues were $8.8 million and $10.3 million, respectively. The decrease in revenue was driven by lower revenue from China of $1.4 million and a decrease in domestic dental revenue of $278,000, of which $179,000 related to an allowance for sales returns due to the termination of a U.S. distributor agreement. Gross profit for the year ended December 31, 2022, was $4.9 million versus $6.3 million for the year ended December 31, 2021. The year-over-year decline in gross profit was driven by lower revenue and the impact of an approximate $0.4 million non-cash inventory reserve related to medical products. Operating loss for the year ended December 31, 2022, was $8.8 million versus $7.4 million for the year ended December 31, 2021.
As of December 31, 2022, the Company had cash and cash equivalents of $8.7 million, working capital of approximately $9.7 million and no debt.
Conference Call
Milestone Scientific’s executive management team will host a conference call today, March 31, 2023, at 8:30 AM Eastern Time to discuss the Company’s financial results for the 2022 fiscal year ending December 31, 2022, as well as the Company’s corporate progress and other developments.
The conference call will be available via telephone by dialing toll-free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and by entering the access code: 333430. A webcast of the call may be accessed at https://www.webcaster4.com/Webcast/Page/2306/47967 or on the Investor Relations section of the Company’s website at https://www.milestonescientific.com/ir-calendar.
An audio replay of the call will be available through April 15, 2023, and can be accessed by dialing 877-481-4010 for U.S. callers or +1 919-882-2331 for international callers and by entering the access code: 45018.
About Milestone Scientific Inc.Milestone Scientific Inc. (MLSS), a technology focused medical research and development company that patents, designs and develops innovative injection technologies and instruments for medical, dental and cosmetic applications. Milestone Scientific’s computer-controlled systems are designed to make injections precise, efficient and increase the overall patient comfort and safety. Their proprietary DPS Dynamic Pressure Sensing Technology® instruments is the platform to advance the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions of subcutaneous drug delivery, including local anesthetic. To learn more, view the MLSS brand video or visit milestonescientific.com.
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2021. The forward-looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Contact: David Waldman or Natalya RudmanCrescendo Communications, LLCEmail: mlss@crescendo-ir.comTel: 212-671-1020
(tables follow)
CONSOLIDATED BALANCE SHEETS
| December 31, 2022 | December 31, 2021 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 8,715,279 | $ | 14,764,346 | ||||
| Accounts receivable, net | 693,717 | 943,272 | ||||||
| Prepaid expenses and other current assets | 443,872 | 375,360 | ||||||
| Inventories | 1,792,335 | 1,541,513 | ||||||
| Advances on contracts | 1,325,301 | 1,309,260 | ||||||
| Total current assets | 12,970,504 | 18,933,751 | ||||||
| Furniture, fixtures and equipment, net | 18,146 | 23,713 | ||||||
| Intangibles, net | 227,956 | 277,619 | ||||||
| Right of use assets | 461,330 | 550,511 | ||||||
| Other assets | 24,150 | 24,150 | ||||||
| Total assets | $ | 13,702,086 | $ | 19,809,744 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,102,729 | $ | 780,428 | ||||
| Accounts payable, related party | 803,492 | 395,857 | ||||||
| Accrued expenses and other payables | 1,124,839 | 1,417,248 | ||||||
| Accrued expenses, related party | 167,549 | 414,241 | ||||||
| Current portion of finance lease liabilities | 9,365 | 8,545 | ||||||
| Current portion of operating lease liabilities | 91,701 | 81,001 | ||||||
| Total current liabilities | 3,299,675 | 3,097,320 | ||||||
| Non-current portion of finance lease liabilities | 10,698 | 20,062 | ||||||
| Non-current portion of operating lease liabilities | 385,279 | 476,980 | ||||||
| Total liabilities | $ | 3,695,652 | $ | 3,594,362 | ||||
| Commitments | ||||||||
| Stockholders’ equity | ||||||||
| Common stock, par value $.001;authorized 100,000,000 shares; 69,306,497 shares issued and 69,273,164 shares outstanding as of December 31, 2022; authorized 100,000,000 shares; 68,153,336 shares issued and 68,120,003 shares outstanding as of December 31, 2021 | 69,306 | 68,153 | ||||||
| Additional paid in capital | 127,478,325 | 124,915,560 | ||||||
| Accumulated deficit | (116,410,405 | ) | (107,704,274 | ) | ||||
| Treasury stock, at cost, 33,333 shares | (911,516 | ) | (911,516 | ) | ||||
| Total Milestone Scientific, Inc. stockholders' equity | 10,225,710 | 16,367,923 | ||||||
| Noncontrolling interest | (219,276 | ) | (152,541 | ) | ||||
| Total stockholders’ equity | 10,006,434 | 16,215,382 | ||||||
| Total liabilities and stockholders’ equity | $ | 13,702,086 | $ | 19,809,744 | ||||
CONSOLIDATED STATEMENTS OF OPERATIONS
YEARS ENDED DECEMBER 31,
| 2022 | 2021 | |||||||
| Product sales, net | $ | 8,805,906 | $ | 10,304,711 | ||||
| Cost of products sold | 3,905,092 | 3,992,811 | ||||||
| Gross profit | 4,900,814 | 6,311,900 | ||||||
| Selling, general and administrative expenses | 12,514,323 | 12,738,362 | ||||||
| Research and development expenses | 1,150,209 | 878,210 | ||||||
| Depreciation and amortization expense | 63,755 | 73,836 | ||||||
| Total operating expenses | 13,728,287 | 13,690,408 | ||||||
| Loss from operations | (8,827,473 | ) | (7,378,508 | ) | ||||
| Interest income (expense) | 54,607 | (16,360 | ) | |||||
| Gain on debt extinguishment-PPP | - | 276,180 | ||||||
| Loss before provision for income taxes and equity investments | (8,772,866 | ) | (7,118,688 | ) | ||||
| Provision for income taxes | - | (333 | ) | |||||
| Loss before equity investment | (8,772,866 | ) | (7,119,021 | ) | ||||
| Deferred profit and divesture-equity investment | - | 242,589 | ||||||
| Net loss | (8,772,866 | ) | (6,876,432 | ) | ||||
| Net loss attributable to noncontrolling interests | 66,735 | 58,115 | ||||||
| Net loss attributable to Milestone Scientific Inc. | $ | (8,706,131 | ) | $ | (6,818,317 | ) | ||
| Net loss per share applicable to common stockholders— | ||||||||
| Basic | (0.12 | ) | (0.10 | ) | ||||
| Diluted | (0.12 | ) | (0.10 | ) | ||||
| Weighted average shares outstanding and to be issued— | ||||||||
| Basic | 70,607,338 | 68,829,860 | ||||||
| Diluted | 70,607,338 | 68,829,860 | ||||||
